Memorial Sloan Kettering Cancer Center

Accepting patients

CFT7455

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Learn more
  • Phase 1/2

Accepting patients

CAMMA-2

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)
Learn more
  • Bispecific Antibody
  • FCRH5
  • Phase 1/2

Accepting patients

CA057-003

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Learn more
  • CELMoD
  • Phase 1/2

Accepting patients

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more
  • CAR T Cell
  • CELMoD
  • GPRC5D
  • Phase 1

Accepting patients

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1

Accepting patients

CARTITUDE-5

Phase 3, Randomized Study comparing Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by an investigational CAR-T versus VRd followed by Lenalidomide and Dexamethasone (RD)Therapy in subjects with newly diagnosed Multiple Myeloma for whom Stem Cell Transplant is not planned as initial therapy
Learn more
  • CAR T Cell
  • BCMA
  • Randomization
  • Phase 3

Not yet accepting

QUINTESSENTIAL

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Learn more
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

Talquetamab Consolidation After BCMA CAR-T

Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Phase 2

Not currently accepting

CARTITUDE-2

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2
  • Has results

Accepting patients

CyBorD Plus Daratumumab

A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)
Learn more
  • Monoclonal Antibody
  • CD38
  • Quadruplet Therapy
  • Phase 2
13 hidden based on your filters. Show All

Filters

Diagnosis

Treatment History

BCMA Therapy

Advanced Filters

Trial Enrollment Status

Classifications

Targets

Trial Type

Phase